Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CSCC

Sanofi reception

Sanofi says it will spin out active ingredient business by 2022

New chief exec Paul Hudson continues revamp

- PMLiVE

As new coronavirus outbreaks emerge, fears of a global pandemic escalate

Increased quarantine measures are reported across the globe

- PMLiVE

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Deal focuses on T cell receptor therapies

- PMLiVE

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC

- PMLiVE

US backs Sanofi’s ‘fast-track’ coronavirus vaccine

Development will tap into earlier work on the SARS virus

- PMLiVE

Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

Solidifies immunotherapy drug's dominance in the setting

- PMLiVE

Sanofi highlights MS drug data as it swings to a loss in Q4

Reported a €10m net loss in the quarter

Sanofi reception

Sanofi indicted in France over epilepsy drug birth defects

Faces allegations over a failure to warn women about risks associated with drug

- PMLiVE

HIV vaccine based on Sanofi/GSK components fails trial

Data suggested vaccine was no more effective than placebo

Sanofi reception

Sanofi’s rare disease drug olipudase alfa scores in late-stage study

Met crucial endpoints across two clinical studies

- PMLiVE

Sanofi completes acquisition of immuno-oncology specialist Synthorx

Synthorx is now fully owned by the French drugmaker

AstraZeneca AZ

AZ’s Imfinzi scores orphan drug status in liver cancer

Company is looking to gain approval in the first-line advanced setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links